FACEmemory®, an Innovative Self-Administered Online Memory Assessment Tool

J Clin Med. 2024 Nov 29;13(23):7274. doi: 10.3390/jcm13237274.

Abstract

Background: Alzheimer's disease (AD) dementia and mild cognitive impairment (MCI) are currently underdiagnosed in the community, and early detection of cognitive deficits is crucial for timely intervention. FACEmemory®, the first completely self-administered online memory test with voice recognition, has been launched as an accessible tool to detect such deficits. This study aims to investigate the neuropsychological associations between FACEmemory subscores and cognitive composites derived from traditional paper-and-pencil neuropsychological tests and to develop an optimal algorithm using FACEmemory data and demographics to discriminate cognitively healthy (CH) individuals from those with MCI. Methods: A total of 669 participants (266 CH, 206 non-amnestic MCI [naMCI], and 197 amnestic MCI [aMCI]) were included. Multiple linear regression analyses were conducted using a cognitive composite as the dependent variable and FACEmemory subscores and demographic data (age, sex, and schooling) as independent variables. Machine learning models were compared to identify an optimal algorithm for distinguishing between CH and MCI (whole MCI, aMCI, and naMCI). Results: Multiple regression analyses showed associations between FACEmemory scores and the domains of memory (ρ = 0.67), executive functions (ρ = 0.63), visuospatial/visuoperceptual abilities (ρ = 0.55), language (ρ = 0.43), praxis (ρ = 0.52), and attention (ρ = 0.31). An optimal algorithm distinguished between CH and aMCI, achieving a FACEmemory cutoff score of 44.5, with sensitivity and specificity values of 0.81 and 0.72, respectively. Conclusions: FACEmemory is a promising online tool for identifying early cognitive impairment, particularly aMCI. It may contribute to addressing the underdiagnosis of MCI and dementia in the community and in promoting preventive strategies.

Keywords: Alzheimer’s disease; digital biomarkers; early detection; memory; mild cognitive impairment; new technologies.

Grants and funding

This work was funded by the research funds of Ace Alzheimer Center Barcelona and was partially supported by funding from the Instituto de Salud Carlos III (ISCIII) Acción Estratégica en Salud, integrated into the Spanish National RCDCI Plan and financed by ISCIII-Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER) grants PI22/01403 and PI19/00335; project TARTAGLIA, Spanish Ministry of Science and Innovation R&D Missions in the Artificial Intelligence program, Spain Digital 2025 Agenda and the National Artificial Intelligence Strategy and financed by the European Union through Next Generation EU funds, under the grant Nº MIA.2021.M02.0005; and from some sponsors (Grifols SA, Life Molecular Imaging GmbH, Araclon Biotech, Laboratorios Echevarne S.A., and Ace Alzheimer Center Barcelona). MB, AR, MM, and MA acknowledge the support of the Spanish ISCIII, Acción Estratégica en Salud, integrated in the Spanish National R+D+I Plan and financed by ISCIII Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER “Una manera de hacer Europa”) grants PI13/02434, PI16/01861, PI17/01474, PI19/01240, PI19/01301, PI19/00335 PI22/00258, and the ISCIII national grant PMP22/00022, funded by the European Union (NextGenerationEU). This work received additional support from CIBERNED (ISCIII) under grants CB06/05/2004 and CB18/05/00010; from the ADAPTED and MOPEAD projects, European Union/EFPIA Innovative Medicines Initiative Joint (grant numbers 115975 and 115985, respectively); from the PREADAPT project, Joint Program for Neurodegenerative Diseases (JPND) grant Nº AC19/00097; from the HARPONE project, Agency for Innovation and Entrepreneurship (VLAIO) grant Nº PR067/21; and from Janssen. The DESCARTES project is funded by the German Research Foundation (DFG).